BioCryst increases ORLADEYO WAC by ~9% to $48,488 per 28-day pack

BIOCRYST PHARMACEUTICALS INC

Effective January 9, 2026, WAC for ORLADEYO (berotralstat) raised from $44,484.33 to $48,487.92 per 28-day pack.
The price increase applies to both the 150mg and 110mg capsule strengths.
BioCryst's sole marketed product ORLADEYO is approved for hereditary angioedema prophylaxis.

item 7.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.